Lexeo Therapeutics Files 8-K for Director/Officer Changes
Ticker: LXEO · Form: 8-K · Filed: Dec 19, 2024 · CIK: 1907108
| Field | Detail |
|---|---|
| Company | Lexeo Therapeutics, Inc. (LXEO) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2024 |
| Risk Level | low |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $1.8 billion, $480,000, $120.0 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Lexeo Therapeutics filed an 8-K detailing leadership changes and compensation plans.
AI Summary
Lexeo Therapeutics, Inc. filed an 8-K on December 18, 2024, reporting changes related to its board of directors and officers, as well as compensatory arrangements. The filing also includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located at 345 Park Avenue South, Floor 6, New York, NY 10010.
Why It Matters
This filing indicates potential shifts in the company's leadership and governance structure, which could impact strategic direction and operational oversight.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate governance and financial information, not indicating immediate operational or financial distress.
Key Players & Entities
- Lexeo Therapeutics, Inc. (company) — Registrant
- December 18, 2024 (date) — Date of earliest event reported
- 345 Park Avenue South, Floor 6, New York, New York 10010 (location) — Principal Executive Offices
- 212 547-9879 (phone_number) — Registrant's Telephone Number
FAQ
What specific changes were made regarding directors or officers?
The filing indicates changes related to 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', but the specific details of these changes are not provided in the provided text.
What financial statements are included in this filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific content of these statements is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 18, 2024.
What is Lexeo Therapeutics, Inc.'s principal executive office address?
Lexeo Therapeutics, Inc.'s principal executive office is located at 345 Park Avenue South, Floor 6, New York, New York 10010.
What is the Commission File Number for Lexeo Therapeutics, Inc.?
The Commission File Number for Lexeo Therapeutics, Inc. is 001-41855.
Filing Stats: 1,778 words · 7 min read · ~6 pages · Grade level 11.2 · Accepted 2024-12-19 07:01:18
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LXEO Nasdaq Glo
- $1.8 billion — Manager for Eventide Asset Management's $1.8 billion healthcare & life sciences fund, a Mana
- $480,000 — led to an initial annual base salary of $480,000, with a discretionary annual bonus targ
- $120.0 m — mpleted an equity financing of at least $120.0 million, then any portion of the Equity A
Filing Documents
- lxeo-20241218.htm (8-K) — 58KB
- lxeo-ex99_1.htm (EX-99.1) — 15KB
- img46940271_0.jpg (GRAPHIC) — 243KB
- 0000950170-24-138224.txt ( ) — 531KB
- lxeo-20241218.xsd (EX-101.SCH) — 25KB
- lxeo-20241218_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release, December 19, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Lexeo Therapeutics, Inc. Date: December 19, 2024 By: /s/ R. Nolan Townsend R. Nolan Townsend, Chief Executive Officer